Interv Akut Kardiol. 2009;8(6):302-306

Insufficient effectiveness of antithrombotic therapy -

Jan Vojáček1, Hana Ševčíková1, Róbert Ševčík1, Josef Bis1, Jaroslav Dušek1, Josef Šťásek1, Miroslav Pecka2

11. interní klinika a LF UK a FN Hradec Králové

22. interní klinika –, oddělení klinické hematologie LF UK a FN Hradec Králové

clinical associations and current opinions on its laboratory assessment

Laboratory demonstration of insufficient platelet inhibition correlates with the clinical incidence of thrombotic complications. What

is missing, however, is the evidence of how to proceed in patients with a laboratory demonstration of insufficient effectiveness of antiplatelet

therapy, i. e. those with increased residual platelet aggregation. According to existing data, it is low (1–8 %) when acetylsalicylic

acid alone is administered when assessing the specific inhibition of arachidonic acid cycle, but more common when assessing the

non-specifically induced platelet aggregation due to a non-COX-1 effect of acetylsalicylic acid (5–30 %). Far more common is the laboratory

ineffectiveness of clopidogrel with established prognostically unfavourable consequences due to CYP450 polymorphisms or in

interaction with other drugs affecting this receptor or clopidogrel absorption. Up to 30 % of patients treated may be affected by the

ineffectiveness of clopidogrel.

Keywords: laboratory ineffectiveness of antiplatelet therapy, thrombotic complications

Published: December 12, 2009  Show citation